DIM (Diindolylmethane) vs Pentadecanoic Acid (C15:0 / Fatty15)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

DIM (Diindolylmethane)Pentadecanoic Acid (C15:0 / Fatty15)
CategorySupplementsSupplements
Standard Dose100-200mg DIM daily
TimingWith meals (fat enhances absorption). Consistent daily dosing for estrogen metabolism modulation.
Cycle Durationongoing or cycle 8-12 weeks on, 4 weeks off
Evidence Levelmoderate_humanEmerging

Mechanism

DIM is formed from indole-3-carbinol (I3C, from cruciferous vegetables) via acid condensation in the stomach. It modulates estrogen metabolism by promoting the 2-hydroxylation pathway (producing 2-hydroxyestrone, considered 'protective' estrogen) over the 16alpha-hydroxylation pathway (producing 16alpha-hydroxyestrone, considered proliferative) and the 4-hydroxylation pathway (producing 4-hydroxyestrone, genotoxic). DIM binds the aryl hydrocarbon receptor (AhR), inducing Phase I (CYP1A1, CYP1A2) and Phase II enzymes that facilitate estrogen detoxification. It also inhibits aromatase and has anti-androgen receptor effects (competitive binding).

Standard Dosing

100-200mg DIM daily

Timing

With meals (fat enhances absorption). Consistent daily dosing for estrogen metabolism modulation.

Cycle Duration

ongoing or cycle 8-12 weeks on, 4 weeks off

Side Effects

  • Harmless dark-colored urine
  • GI upset
  • Headache
  • Changes in menstrual cycle
  • Potential anti-androgenic effects at high doses in men

Contraindications

  • Estrogen-dependent conditions where estrogen reduction is not desired
  • Concurrent tamoxifen/AI therapy (without oncologist approval)
  • Pregnancy/lactation

Best Stacking Partners

Calcium D-Glucarate (Phase II estrogen clearance)SulforaphaneNACMilk Thistle

Mechanism

Odd-chain saturated fatty acid identified as essential. Strengthens cell membranes by integrating into phospholipid bilayer, activates AMPK and PPAR-alpha/delta, and inhibits mTOR. Repairs mitochondrial function. Epidemiologically associated with reduced cardiometabolic disease.

Contraindications

  • None established

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →